MedDataX Logo

24-Wk β-Alanine Ingestion on Muscle Taurine and Clinical Blood Parameters in Healthy Males

NCT ID: NCT03655041

Last Updated: 2018-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-01

Study Completion Date

2017-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although β-alanine (BA) has been shown to be an effective ergogenic aid, little information exists on the safety of chronic supplementation despite potential concerns. The aim of this study was to investigate the effects of chronic BA supplementation on muscle taurine content, blood clinical markers and sensory side-effects during 24 weeks of BA supplementation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sports Nutritional Physiological Phenomena

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Physiological Phenomena

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beta-Alanine

6.4 g/day of beta-alanine for 24 weeks

Group Type EXPERIMENTAL

Beta-alanine

Intervention Type DIETARY_SUPPLEMENT

Beta-alanine in sustained-release tablets to increase muscle carnosine content

Placebo

6.4 g/day of maltodextrin for 24 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beta-alanine

Beta-alanine in sustained-release tablets to increase muscle carnosine content

Intervention Type DIETARY_SUPPLEMENT

Placebo

Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males

Exclusion Criteria

* Smokers
* Chronic disease
* Prior or current use of steroids
* Use of creatine in the last 6 months
* Use of beta-alanine in the last 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Sao Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bruno Gualano

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruno Gualano, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Sao Paulo

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24WKBA

Identifier Type: -

Identifier Source: org_study_id